Page last updated: 2024-11-08

cleistopholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cleistopholine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID457732
CHEMBL ID444067
SCHEMBL ID6358965
MeSH IDM0499318

Synonyms (8)

Synonym
cleistopholine
CHEMBL444067
96889-94-0
4-methylbenzo(g)quinoline-5,10-dione
c14h9no2
SCHEMBL6358965
GVRYUHXXENMGEV-UHFFFAOYSA-N
DTXSID30242618

Research Excerpts

Overview

Cleistopholine is a natural alkaloid present in plants with numerous biological activities.

ExcerptReferenceRelevance
"Cleistopholine is a natural alkaloid present in plants with numerous biological activities. "( Cleistopholine isolated from Enicosanthellum pulchrum exhibits apoptogenic properties in human ovarian cancer cells.
Ali, HM; Dehghan, F; Hashim, NM; Karimian, H; Majid, NA; Mohan, S; Nordin, N; Rahman, MA, 2016
)
3.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID360353Cytotoxicity against human HepG2(2.2.15) cells by MTT assay2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic constituents of the fruits of Cananga odorata.
AID1668165Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl alpha-D-glucoside as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by colorimetric assay2020Bioorganic & medicinal chemistry, 05-15, Volume: 28, Issue:10
α-Glucosidase inhibitory and nitric oxide production inhibitory activities of alkaloids isolated from a twig extract of Polyalthia cinnamomea.
AID39700In vitro antifungal activity against Aspergillus fumigatus ATCC 26934.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Copyrine alkaloids: synthesis, spectroscopic characterization, and antimycotic/antimycobacterial activity of A- and B-ring-functionalized sampangines.
AID245052Minimum inhibitory concentration against Schizosaccharomyces pombe2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID336957Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio
AID336956Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID244927Minimum inhibitory concentration against Escherichia coli2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID244893Minimum inhibitory concentration against Mucor mucedo2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID45479In vitro antifungal activity against Candida albicans B311.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Copyrine alkaloids: synthesis, spectroscopic characterization, and antimycotic/antimycobacterial activity of A- and B-ring-functionalized sampangines.
AID360352Cytotoxicity against human HepG2 cells by MTT assay2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic constituents of the fruits of Cananga odorata.
AID336959Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio
AID244976Minimum inhibitory concentration against Rhizopus chinensis2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID244917Minimum inhibitory concentration against Candida utilis2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID244928Minimum inhibitory concentration against Proteus vulgaris2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID245030Minimum inhibitory concentration against Penicillium chrysogenum2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID55038In vitro anti-mycobacterial activity against Cryptococcus neoformans ATCC 32264.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Copyrine alkaloids: synthesis, spectroscopic characterization, and antimycotic/antimycobacterial activity of A- and B-ring-functionalized sampangines.
AID336960Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio
AID336953Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID336954Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID336958Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio
AID774608Antimicrobial activity against Mycobacterium intracellulare2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and antimycobacterial activity of analogues of the bioactive natural products sampangine and cleistopholine.
AID245019Minimum inhibitory concentration against Pseudomonas aeruginosa2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID245041Minimum inhibitory concentration against Saccharomyces cerevisiae2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID244960Minimum inhibitory concentration against Rhodotorula rubra2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID336955Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID144140In vitro anti-mycobacterial activity against Mycobacterium intracellular ATCC 23068. 1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Copyrine alkaloids: synthesis, spectroscopic characterization, and antimycotic/antimycobacterial activity of A- and B-ring-functionalized sampangines.
AID244959Minimum inhibitory concentration against Bacillus subtilis2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID244958Minimum inhibitory concentration against Aspergillus niger2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID245006Minimum inhibitory concentration against Staphylococcus aureus2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Structure-activity relations of azafluorenone and azaanthraquinone as antimicrobial compounds.
AID1872633Antibacterial activity against Mycobacterium tuberculosis incubated for 5 days by Alamar blue staining method2022European journal of medicinal chemistry, Mar-15, Volume: 232Quinoline heterocyclic containing plant and marine candidates against drug-resistant Mycobacterium tuberculosis: A systematic drug-ability investigation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's4 (40.00)29.6817
2010's3 (30.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]